Document is current
Any future updates will be listed below
-
Authors
Spring, Laura M.
Clark, Shealagh L.
Li, Tianyu
Goel, Shom
Tayob, Nabihah
Viscosi, Elene
Abraham, Elizabeth
Juric, Dejan https://orcid.org/0000-0003-2983-7704
Isakoff, Steven J.
Mayer, Erica https://orcid.org/0000-0001-5430-8957
Moy, Beverly
Supko, Jeffrey G.
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
Bardia, Aditya https://orcid.org/0000-0003-4885-1157
- License Information
-
More Information
Article History
Received: 19 January 2021
Accepted: 25 June 2021
First Online: 4 August 2021
Competing interests
: L.M.S. declares the following relationships: Consultant/advisory board: Novartis, Lumicell, Puma Biotechnology, Avrobio. S.G. is the recipient of research funding from Eli Lilly and Co which has been used to support a part of this work. S.G. has served as a paid advisory board member for Eli Lilly and Co, G1 Therapeutics, Pfizer, and Novartis. S.G. also conducts laboratory research sponsored by G1 Therapeutics and clinical research sponsored by Eli Lilly and Co and by Novartis. D.J. declares the following relationships: Consulting: Novartis, Genentech, EMD Serono, Eisai, Ipsen, Syros, Vibliome Therapeutics, Relay Therapeutics, MapKure, Petra Pharma, Silverback Therapeutics; Research funding (to the institution); Novartis, Genentech, Eisai, EMD Serono, Pfizer, Syros, Takeda, Amgen, InventisBio, Dizal Pharma, Celgene, Infinity Pharmaceuticals. SJI declares the following relationships: Consulting or advisory roles with Abbvie, PharmaMar, Genentech/Roche, Myriad Genetics, Hengrui Therapeutics, Puma Technology, and Immunomedics, institutional research funding from Genentech, PharmaMar, Abbvie, OncoPep, Merck, and AstraZeneca/MedImmune, and travel support from PharmaMar. B.M. declares the following relationships: Research funding (institution): PUMA Biotechnology and reports her spouse is a consultant for MOTUS GI. S.M.T. receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odonate, Sanofi, and Nektar. SMT has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Paxman, Athenex, Oncopep, Daiichi-Sankyo, G1 Therapeutics, Gilead, Silverback Therapeutics, Kyowa Kirin Pharmaceuticals, AbbVie, Sanofi, Seattle Genetics, Celldex, Bristol-Myers Squibb and Nanostring. A.B. declares the following relationships: consultant/advisory board: Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Spectrum Pharma, Taiho Pharm, Diiachi, Sanofi, Puma Biotechnology; Research Grant (self): Biothernostics; Research Grant (Institution): Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Sanofi, Mersana. The remaining authors declare no competing interests.
